CGIX has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Cancer Genetics from a sell rating to a hold rating in a research report on Wednesday, November 29th. ValuEngine downgraded shares of Cancer Genetics from a sell rating to a strong sell rating in a research report on Friday, December 1st. Finally, Maxim Group initiated coverage on shares of Cancer Genetics in a report on Thursday, December 7th. They set a buy rating and a $6.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $5.56.
Shares of Cancer Genetics (CGIX) traded down $0.05 during trading hours on Tuesday, hitting $2.00. 316,787 shares of the company were exchanged, compared to its average volume of 196,873. The firm has a market cap of $55.41, a P/E ratio of -2.44 and a beta of 1.10. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics has a 1-year low of $1.65 and a 1-year high of $5.30.
In related news, Director John Pappajohn bought 150,000 shares of the company’s stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $1.86 per share, for a total transaction of $279,000.00. Following the acquisition, the director now owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 21.30% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Northern Trust Corp raised its holdings in Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after buying an additional 12,168 shares during the period. Granahan Investment Management Inc. MA raised its holdings in Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after buying an additional 49,371 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after buying an additional 197,619 shares during the period. Hedge funds and other institutional investors own 11.13% of the company’s stock.
WARNING: This article was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3143182/cancer-genetics-cgix-given-a-6-00-price-target-at-hc-wainwright.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.